Cavernous angioma overview

Jump to navigation Jump to search

Cavernous angioma Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Cavernous angioma from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

CT

MRI

MRA

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Cavernous angioma overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cavernous angioma overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cavernous angioma overview

CDC on Cavernous angioma overview

Cavernous angioma overview in the news

Blogs on Cavernous angioma overview

Directions to Hospitals Treating Cavernous angioma

Risk calculators and risk factors for Cavernous angioma overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Edzel Lorraine Co, DMD, MD

Overview

Cavernous angioma, also known as cerebral cavernous malformation (CCM) or cavernoma, is a rare disease that involves the capillaries of the central nervous system. CCMs have dilated endothelial-lined sinusoidal capillaries which lack intervening neural tissue. This is the only characteristic that can distinguish these lesions from capillary telangiectasia.

CCMs can be classified as sporadic or familial, which has an autosomal dominant form of inheritance. The majority of CCMs are recent and remote hemorrhages. These lesions range in size from millimeters to almost less than 3 centimeters in diameter.

Historical Perspective

Cavernous angioma, also known as cavernous hemangioma, cavernoma, and cerebral cavernous malformation, is a vascular malformation with still an unclear history of its first clinical discovery.

Pathophysiology

Developmental venous anomaly (DVA) can cause a chronic increase in intracranial pressure which can form microhemorrhages around DVA, leading to the development and growth of cavernous angioma. There are two patterns of cavernous angioma, the sporadic and the familial pattern.

Causes

There are no established causes for cavernous angioma.

Differentiating Cavernous angioma from other Diseases

Cavernous angioma appears very similar on magnetic resonance with calcified neoplastic and hemorrhagic lesions, most especially renal cell carcinoma, melanoma, pleomorphic xanthoastrocytomas, and oligodendrogliomas.

Epidemiology and Demographics

Cavernous angioma is the second most common form of intravascular malformation next to the developmental venous anomaly (DVA). The incidence in the general population is between 0.1–0.5%, and clinical symptoms typically appear between 30 to 50 years of age. Once thought to be strictly congenital, these vascular lesions have been found to occur de novo.

Risk Factors

Family history increases the risk of having cavernous angioma. Genetic testing is recommended for the pathogenic variants of cavernous angioma (KRIT1, MGC4607, and PDCD10).

Natural History, Complications, and Prognosis

Cavernous angioma is usually a benign course since it is a low-flow and low-pressure lesion. Patients with cavernous angioma have variable signs and symptoms, with seizure as the most predominant symptom, followed by hemorrhage and focal neurologic deficit.

Diagnosis

History and Symptoms

CCMs have varying presentations and these can be in the form of hemorrhagic stroke, focal neurological deficits, recurrent headaches, and seizures. Howevever, CCMs can be asymptomatic sometimes.

Physical Examination

Cavernous angioma, also known as cavernous hemangioma, can affect several organs. Diagnosing this condition should be correlated with imaging findings.

CT scan

CT scan is not usually used as a primary modality to diagnose cavernous angiomas due to inablility to detect smaller lesions despite the ability to detect lesions complicated by calcification or hemorrhage.

MRI

Diagnosis is most commonly made accidentally by routine magnetic resonance imaging (MRI) screening, but not all MRI exams are created equal. It is paramount that the patient request a gradient-echo sequence in order to unmask small or punctate lesions which may otherwise remain undetected. These lesions are also more conspicuous on FLAIR imaging compared to standard T2 weighing. FLAIR imaging is different from Gradient sequences, rather, it is similar to T2 weighing but suppresses free-flowing fluid signal. Sometimes quiescent CCMs can be revealed as incidental findings during MRI exams ordered for other reasons.

MRA

Sometimes the lesion appearance imaged by MRI remains inconclusive. Consequently neurosurgeons will order a cerebral angiogram or magnetic resonance angiogram (MRA). Since CCMs are low flow lesions (they are hooked into the venous side of the circulatory system), they will be angiographically occult (invisible). If a lesion is discernible via angiogram in the same location as in the MRI, then an arteriovenous malformation (AVM) becomes the primary concern.

Other Imaging Findings

There are no other imaging findings associated with cavernous angioma.

Other Diagnostic Studies

Diagnostic biomarkers can be utilized too in conjunction with imaging tools to identify cavernous angioma.

Treatment

Surgery

Surgery is the mainstay treatment for cavernous angioma. Complete surgical resection should be done to prevent seizures and hemorrhage due to remnant tissue.

Cost-effectiveness of therapy

Since cavernous angioma can be treated via medical or surgical option, therapy for this condition is relatively cost-effective.

Futures of Investigational Therapies

Several insights on development of cavernous angioma exist. Some drugs have been identified to be able to reduce risk of hemorrhage, and possible development of new lesions. Advances in biomarkers are now being studied more.

References